REATORG is:
Integrated approach
Best possible price/quality ratio
Own logistics department
Own production facility
- United Call Center
- +7 (495) 966 31 40
- +7 (800) 775 32 11
- Free of charge for Russia
- reatorg@reatorg.ru
FOR INVESTORS
Bonds of REATORG LLC
REATORG LLC is a company established in 2011 and providing a wide range of services from the supply of raw materials and materials to the implementation of integrated solutions with the design, supply and delivery of turnkey projects. The company works with various enterprises, both with organizations of small and medium, and large businesses. Among our customers are the largest enterprises in the pharmaceutical and chemical industries.
Sergey Prudnikov,
CEO of REATORG LLC
The REATORG company carries out design and complex equipment of chemical and pharmaceutical productions and laboratories: the equipment, technological pipelines, devices, consumables, furniture, glassware, reagents.
REATORG is an official distributor and supplier of products from leading European, American and Asian manufacturers: Agilent, Merck, Huber, Top Industrie, ChargePoint, Metrohm, ViBRA, DWK (Duran, Wheaton, Kimble), Sigma-Aldrich, abcr, Waldner, AGT, Tailin BioEngineering, Purui, Huada, Lneya and others.
REATORG is a developer and manufacturer of equipment for low-tonnage chemistry under its own brand REATORG TECHNOLOGIES™: reactor systems, rectification and distillation systems, vessels, scrubbers and absorption columns.
The integrated approach of REATORG when organizing a new or upgrading an existing production facility allows you to save time, optimize costs and protect the Customer's investment, as the technology and quality of the final product are at the forefront!
CREDIT RATING
BB+
Forecast "Stable"
Forecast "Stable"
Key factors of the National Rating Agency according to a press release dated 10/24/2022
- Long term of work in the market: the Company has been operating for more than 10 years;
- Low dependence on suppliers of products: the share of the largest supplier in the cost does not exceed 20%;
- Simple ownership structure: a single beneficiary directly owns 100% of the Company;
- High credit quality of the pharmaceutical industry. Potential for growth in demand for the organization of production;
- Comfortable debt load. Attraction of financing from the bond market in the amount of 200 million rubles. will lead to a moderate increase in the balance sheet debt burden to 3x Net Debt/EBITDA
TERMS AND CONDITIONS OF THE FIRST (DEBUT) ISSUE OF BONDS
%
High coupon
Benefits for personal income tax
Depreciation
Quarterly paymentCONTACTS
